Abstract:Highlights • Inhibition of MyD88 attenuates cerebral ischemia-reperfusion injury in mice. • MyD88 activates microglia via IRF5 following cerebral ischemia-reperfusion(CIR) • MyD88 participates in blood-brain barrier damage following CIR. Myeloid differentiation primary response gene 88 (MyD88), a downstream molecule directly linked to Toll-like receptor (TLRs) and IL1 receptor, has been implicated in ischemia-reperfusion injury across various organs. However, its role in cerebral ischemia-reperfusion injury (CIRI) remains unclear. Five transient middle cerebral artery occlusion (tMCAO) microarray datasets were obtained from the Gene Expression Omnibus (GEO) database. We screened these datasets for differentially expressed genes (DEGs) using the GSE35338 and GSE58720 datasets and performed weighted gene co-expression network analysis (WGCNA) using the GSE30655, GSE28731, and GSE32529 datasets to identify the core module related to tMCAO. A protein-protein interaction (PPI) network was constructed using the intersecting DEGs and genes in the core module. Finally, we identified Myd88 was the core gene. In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) validated that TNFα, IL17, and MyD88 signaling pathways were significantly enriched in tMCAO. Subsequently, we investigated the mechanistic role of MyD88 in the tMCAO model using male C57BL/6 mice. MyD88 expression increased significantly 24h after reperfusion. After intraperitoneal administration of TJ-M2010-5, a MyD88-specific inhibitor, during reperfusion, the infarction volumes in the mice were ameliorated. TJ-M2010-5 inhibits the activation of microglia and astrocytes. Moreover, it attenuates the upregulation of inflammatory cytokines TNFα, IL17, and MMP9 while preserving the expression level of ZO1 after tMCAO, thereby safeguarding against BBB disruption. Finally, our findings suggest that MyD88 regulates the IRAK4/IRF5 signaling pathway associated with microglial activation. MyD88 participates in CIRI by regulating the inflammatory response and BBB damage following tMCAO.

Inhibition of MyD88 by a Novel Inhibitor Reverses Two-Thirds of the Infarct Area in Myocardial Ischemia and Reperfusion Injury

Pharmacological Inhibition Of Myd88 Homodimerization Counteracts Renal Ischemia Reperfusion-Induced Progressive Renal Injury In Vivo And In Vitro

MyD88 inhibition attenuates cerebral ischemia-reperfusion injury by regulating the inflammatory response and reducing blood-brain barrier damage

TJ-M2010-5, a novel CNS drug candidate, attenuates acute cerebral ischemia-reperfusion injury through the MyD88/NF-κB and ERK pathway

A Novel Inhibitor of Homodimerization Targeting MyD88 Ameliorates Renal Interstitial Fibrosis by Counteracting TGF-β1-Induced EMT in Vivo and in Vitro

Short-term Use of MyD88 Inhibitor TJ-M2010-5 Prevents D-Galactosamine/lipopolysaccharide-induced Acute Liver Injury in Mice.

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Role of JNK Signalling Pathway and Platelet‑lymphocyte Aggregates in Myocardial Ischemia‑reperfusion Injury and the Cardioprotective Effect of Ischemic Postconditioning in Rats.

MRTF-A alleviates myocardial ischemia reperfusion injury via inhibiting TLR4/TRIF signaling pathways

Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.

MG53 Protein: A Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury

MiR-129-5p Protects Against Myocardial Ischemia-Reperfusion Injury Via Targeting HMGB1

Abstract 99: Conditional Depletion of CD11c + Cells Attenuates Myocardial Ischemia-Reperfusion Injury in Mice

IL‐38 attenuates myocardial ischemia–reperfusion injury by inhibiting macrophage inflammation

Activated Regulatory T-cells Attenuate Myocardial Ischaemia/reperfusion Injury Through a CD39-dependent Mechanism.

Down-Regulation of Mir-327 Alleviates Ischemia/Reperfusion-Induced Myocardial Damage by Targeting RP105

Tregs Biomimetic Nanoparticle to Reprogram Inflammatory and Redox Microenvironment in Infarct Tissue to Treat Myocardial Ischemia Reperfusion Injury in Mice

Blockade of the Notch Signaling Pathway Promotes M2 Macrophage Polarization to Suppress Cardiac Fibrosis Remodeling in Mice With Myocardial Infarction

RP105 Protects Against Apoptosis in Ischemia/Reperfusion-Induced Myocardial Damage in Rats by Suppressing TLR4-Mediated Signaling Pathways

Blocking the MyD88-dependent Pathway Protects the Myocardium from Ischemia/reperfusion Injury in Rat Hearts.

Author Correction: Inhibition of Myeloid Differentiation Primary Response Protein 88 Provides Neuroprotection in Early Brain Injury Following Experimental Subarachnoid Haemorrhage